Ultime notizie per LeMaitre Vascular (NASDAQ:LMAT) Azioni

LEMAITRE VASCULAR INC

LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

LeMaitre Vascular Inc

WIIM

LMAT

LeMatire Vascular shares are trading lower after the company reported Q1 EPS guidance below estimates and lowered its FY25 EPS guidance.

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) lowers FY2025 GAAP EPS guidance from $2.15-$2.32 to $2.07-$2.24 vs $2.24 analyst estimate. Raises FY2025 sales outlook from $235.40 million-$242.80 million to $242.00 million-$249.00 million vs $239.26 million estimate.

News

Guidance

LeMaitre Vascular Lowers FY2025 GAAP EPS Guidance from $2.15-$2.32 to $2.07-$2.24 vs $2.24 Est; Raises FY2025 Sales Guidance from $235.40M-$242.80M to $242.00M-$249.00M vs $239.26M Est

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) is looking for Q2 GAAP EPS of $0.55-$0.59 vs $0.58 analyst estimate. sees sales of $61.500 million-$63.500 million vs $60.87 million analyst estimate.

LeMaitre Vascular Sees Q2 GAAP EPS $0.55-$0.59 vs $0.58 Est; Sees Sales $61.500M-$63.500M vs $60.87M Est

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.48 per share which missed the analyst consensus estimate of $0.50 by 4 percent. This is a 9.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $59.87 million which beat the analyst consensus estimate of $57.64 million by 3.87 percent. This is a 11.95 percent increase over sales of $53.48 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

LeMaitre Vascular Q1 EPS $0.48 Misses $0.50 Estimate, Sales $59.87M Beat $57.64M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate LeMaitre Vascular to report an earnings per share (EPS) of $0.50.
The market awaits LeMaitre Vascular's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 8.07% drop in the share price the next day.
Here's a look at LeMaitre Vascular's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.43</td>
<td>0.47</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.49</td>
<td>0.53</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039689_0.png" alt="eps graph" />
<h3>Performance of LeMaitre Vascular Shares</h3>
Shares of LeMaitre Vascular were trading at $92.6 as of April 29. Over the last 52-week period, shares are up 34.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on LeMaitre Vascular</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on LeMaitre Vascular.
The consensus rating for LeMaitre Vascular is Buy, derived from 3 analyst ratings. An average one-year price target of $105.0 implies a potential 13.39% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of NovoCure, Enovis and QuidelOrtho, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for NovoCure, with an average 1-year price target of $29.67, suggesting a potential 67.96% downside.</li>
<li>Analysts currently favor an Buy trajectory for Enovis, with an average 1-year price target of $64.0, suggesting a potential 30.89% downside.</li>
<li>Analysts currently favor an Neutral trajectory for QuidelOrtho, with an average 1-year price target of $43.67, suggesting a potential 52.84% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for NovoCure, Enovis and QuidelOrtho, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LeMaitre Vascular</td>
<td>Buy</td>
<td>13.98%</td>
<td>$38.59M</td>
<td>3.35%</td>
</tr>
<tr>
<td>NovoCure</td>
<td>Neutral</td>
<td>11.91%</td>
<td>$116.47M</td>
<td>-9.50%</td>
</tr>
<tr>
<td>Enovis</td>
<td>Buy</td>
<td>23.29%</td>
<td>$307.52M</td>
<td>-23.87%</td>
</tr>
<tr>
<td>QuidelOrtho</td>
<td>Neutral</td>
<td>-4.69%</td>
<td>$326.10M</td>
<td>-5.78%</td>
</tr>
</tbody>
</table>

Key Takeaway:
LeMaitre Vascular ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, LeMaitre Vascular is positioned favorably compared to its peers in terms of financial performance.
<h3>About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: LeMaitre Vascular's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 13.98%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: LeMaitre Vascular's net margin is impressive, surpassing industry averages. With a net margin of 20.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): LeMaitre Vascular's ROE excels beyond industry benchmarks, reaching 3.35%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): LeMaitre Vascular's ROA stands out, surpassing industry averages. With an impressive ROA of 2.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.
<a href="https://www.benzinga.com/quote/LMAT/earnings">To track all earnings releases for LeMaitre Vascular visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at LeMaitre Vascular's Upcoming Earnings Report

Lake Street analyst Brooks O'Neil maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Buy and raises the price target from $105 to $110.

Price Target

Analyst Ratings

Lake Street Maintains Buy on LeMaitre Vascular, Raises Price Target to $110

Citizens Capital Markets analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Buy and raises the price target from $105 to $110.

Citizens Capital Markets Maintains Buy on LeMaitre Vascular, Raises Price Target to $110

LeMaitre Vascular shares are trading lower after Barrington Research downgraded the stock from Outperform to Market Perform.

Barrington Research analyst Michael Petusky downgrades LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) from Outperform to Market Perform.

Downgrades

Barrington Research Downgrades LeMaitre Vascular to Market Perform

LeMaitre Vascular shares are trading lower after the company reported worse-than-expected Q4 sales results.

LeMaitre Vascular Q4 2024 Adj. EPS $0.49, Inline, Sales $55.70M Miss $55.96M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CVEO

CYTK

DAIO

DCGO

DELL

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Wells Fargo analyst Nathan Treybeck initiates coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Equal-Weight rating and announces Price Target of $95.

Initiation

Wells Fargo Initiates Coverage On LeMaitre Vascular with Equal-Weight Rating, Announces Price Target of $95

Management

LeMaitre Vascular Appointed As CFO, Effective March 10, 2025

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 178.2% to $9.04 during Tuesday's pre-market session. The company's market cap stands at $10.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 137.73% to $1.26. The market value of their outstanding shares is at $235.4 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares rose 39.15% to $8.85. The company's market cap stands at $178.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) stock rose 27.53% to $1.26. The market value of their outstanding shares is at $33.3 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares moved upwards by 19.13% to $19.67. The market value of their outstanding shares is at $22.2 billion. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 17.99% to $1.18. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock decreased by 47.7% to $1.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares decreased by 38.27% to $1.42. The company's market cap stands at $47.4 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares decreased by 33.49% to $3.0. The market value of their outstanding shares is at $97.7 million. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) stock declined by 31.25% to $1.98. The company's market cap stands at $156.8 million. </li>
<li>LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) stock declined by 23.79% to $70.19. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 12.49% to $5.12. The company's market cap stands at $185.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKTX

BMEA

CAMP

PEPG

PLRZ

PRTG

RVPH

TEVA

TNXP

TNYA

VCNX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Reported Earlier, LeMaitre Vascular Announces $150M 2.50% Convertible Senior Notes Due 2030, With 30% Premium Conversion Pricing

LeMaitre Vascular, Inc. ("LeMaitre") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes.

Offerings

LeMaitre Vascular Announces Proposed $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

A large exercise of company stock options by James John OConnor, Director at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) was disclosed in a new SEC filing on November 27, as part of an insider exercise.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924036352//Archives/edgar/data/1158895/000143774924036352/0001437749-24-036352-index.htm">U.S. Securities and Exchange Commission</a>, OConnor, Director at LeMaitre Vascular, exercised stock options for 7,500 shares of LMAT. The transaction value amounted to $527,400.
LeMaitre Vascular shares are trading up 0.36% at $105.8 at the time of this writing on Thursday morning. Since the current price is $105.8, this makes OConnor's 7,500 shares worth $527,400.
<h3>All You Need to Know About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>LeMaitre Vascular: Delving into Financials</h3>
Revenue Growth: LeMaitre Vascular displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 15.63%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 67.82%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.5.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.06, LeMaitre Vascular adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 57.93, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 11.21, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 36.81, LeMaitre Vascular could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Strategic Sale: James John OConnor Decides To Exercise Options Worth $527K At LeMaitre Vascular

Press Releases

LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering

Financing

LeMaitre Vascular Prices $150 Million Convertible Senior Notes

LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025

LeMaitre Q4 2024 Financial Results

LeMaitre to Participate at Upcoming Investor Conferences in March

Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference

LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

LeMaitre Q1 2025 Financial Results

LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

Comments

LeMaitre Vascular

Notizie

Ultime notizie per LeMaitre Vascular (NASDAQ:LMAT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO